Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...
BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 ...
Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...
Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...
(Ensifentrine + glycopyrrolate) is under clinical development by Verona Pharma and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for ...
Verona Pharma has agreed a new $400 million debt facility ... its therapy for chronic obstructive pulmonary disease (COPD). The Anglo-US company has already tapped $50 million of the funding ...
Investing.com - Investors should expect some moderation in growth in the S&P 500 in 2025 after two years of over 20% expansion in the benchmark index, according to ...
In recent trading, shares of Verona Pharma plc (Adderbury) (Symbol: VRNA) have crossed above the average analyst 12-month target price of $47.28, changing hands for $48.20/share. When a stock ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...